SCHEMBL731378

SCHEMBL731378

O=P(O)(O)C(NCCNC(P(=O)(O)O)P(=O)(O)O)P(=O)(O)O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 4/20 0.39
KDM4E B2RXH2 1/20 0.39
THRB P10828 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CA12 O43570 5/20 0.37
CA9 Q16790 1/20 0.37
ANPEP P15144 4/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 1/20 0.36
TYMS P04818 1/20 0.35
ERAP2 Q6P179 1/20 0.35
MMP8 P22894 2/20 0.34
MMP9 P14780 1/20 0.34
MMP14 P50281 1/20 0.34
ENO1 P06733 1/20 0.33
LAP3 P28838 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10710751 0.87 LAP3 (0.32) MMP2KDM4ETHRBMAPK1HSD17B10
SCHEMBL285956 0.85 CA12 (0.33) MMP2KDM4ETHRBMAPK1HSD17B10
SCHEMBL17187190 0.85 S1PR2 (0.40) MMP2KDM4ETHRBMAPK1HSD17B10
SCHEMBL9711407 0.83 TYMS (0.35) MMP2KDM4ETHRBMAPK1HSD17B10
(Propylamino)Methylenediphosphonic Acid SCHEMBL8817761 0.83 MMP2 (0.50) MMP2ANPEPERAP2MMP9LAP3
SCHEMBL8761864 0.81 FDPS (0.48) MMP2KDM4ETHRBMAPK1HSD17B10
SCHEMBL10613308 0.81 ANPEP (0.34) MMP2KDM4ETHRBMAPK1HSD17B10
SCHEMBL18230241 0.81 ANPEP (0.53) KDM4ECA12CA9ANPEPCA1
SCHEMBL4368473 0.79 BLM (0.48) HSD17B10CA12CA9ANPEPCA2
SCHEMBL11296817 0.79 FOLH1 (0.45) CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11963761-B2 Mediation of in vivo analyte signal degradation SENSEONICS, INCORPORATED (US) 2024-04-23 US claimed
EP-3204037-B1 COMPOSITIONS AND KITS FOR ENZYMATIC DEBRIDEMENT AND METHODS OF USING THE SAME ROCHAL TECH LLC (US) 2022-12-07 EP claimed
EP-3204038-B1 COMPOSITIONS COMPRISING AMYLASE FOR USE IN THE TREATEMENT OF PRURITUS ROCHAL TECH LLC (US) 2022-05-04 EP claimed
EP-3847889-A1 BIOCIDAL COMPOSITIONS COMPRISING IRON CHELATORS Arch Chemicals, Inc. (US) 2021-07-14 EP claimed
US-20200359943-A1 MEDIATION OF IN VIVO ANALYTE SIGNAL DEGRADATION SENSEONICS, INCORPORATED (US) 2020-11-19 US claimed
EP-2787985-B1 BIOCIDAL COMPOSITIONS AND METHODS OF USING THE SAME ROCHAL IND LLC (US) 2020-07-01 EP claimed
US-10688159-B2 Compositions and kits for treating pruritus and methods of using the same ROCHAL INDUSTRIES, LLC (US) 2020-06-23 US claimed
US-20200170249-A1 Biocidal Compositions Comprising Iron Chelators ARCH CHEMICALS, INC. 2020-06-04 US claimed
EP-1760737-B1 USE OF AN ELECTROLYTE FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR RUBYCON CORP (JP) 2018-10-31 EP claimed
EP-3204037-A1 COMPOSITIONS AND KITS FOR ENZYMATIC DEBRIDEMENT AND METHODS OF USING THE SAME Rochal Industries, LLC (US) 2017-08-16 EP claimed
US-20130150451-A1 BIOCIDAL COMPOSITIONS AND METHODS OF USING THE SAME ROCHAL INDUSTRIES, LLP (US) 2013-06-13 US claimed
EP-1755576-A4 ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE DERMCARE VET PTY LTD (AU) 2009-07-08 EP claimed
EP-1755576-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE DERMCARE-VET PTY LTD (AU) 2007-02-28 EP claimed
EP-1017427-B1 USE OF A COMPOSITION COMPRISING A CHELATING AGENT AND AN ANTIMICROBIAL COMPOUND FOR THE TREATMENT OF BIOFILMS UNIV TEXAS (US) 2006-04-26 EP claimed
EP-1006536-B1 Electrolytic solution for electrolytic capacitor and electrolytic capacitor using the same RUBYCON CORP (JP) 2006-03-15 EP claimed
WO-2005097094-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE DERMCARE-VET PTY LTD (AU) 2005-10-20 WO claimed
US-6267979-B1 PROVIDINY AQUEOUS SYSTEM FORMULATION COMPRISING CHELATING AGENT, AN ANTIMICROBIAL TO CONTROL GROWTH OF MICROORGANISMS WAKE FOREST UNIVERSITY 2001-07-31 US claimed
US-4285575-A USING AN ELECTROCHROMIC ELECTROLYTE CONTAINING A CARBOXYLIC-CONTAINING COMPLEXING AGENT, A FERROUS SALT, A METAL SALT, AND A CHROMOGEN; DURABILITY CANON KABUSHIKI KAISHA (JP) 1981-08-25 US claimed
US-4212518-A ELECTROCHROMIC CELL CANON KABUSHIKI KAISHA (JP) 1980-07-15 US claimed
US-4073700-A FROM GOLD CYANIDE IN THE PRESENCE OF A CHELATING AGENT WEISBERG ALFRED M 1978-02-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200170249-A1 Biocidal Compositions Comprising Iron Chelators SLC40A1, TFRC, SLC39A14 MMP2 1241/4885KDM4E 3199/4885THRB 4425/4885
US-20130150451-A1 BIOCIDAL COMPOSITIONS AND METHODS OF USING THE SAME GCG, BID, DGAT1 MMP2 235/4885KDM4E 3836/4885THRB 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.